Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Pentadecapeptide BPC-157 Arginate (BPC-ARG) is a healing peptide, at the preclinical stage in the published literature. Arginine salt form of BPC-157 with enhanced stability and potentially improved bioavailability compared to acetate form.
Arginine salt form of BPC-157 with enhanced stability and potentially improved bioavailability compared to acetate form.
| Research Status | Preclinical |
|---|---|
| Half-Life | 4-6 hours |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 250-500 mcg |
Same as BPC-157 with arginine counter-ion for improved stability in aqueous solutions.
Arginine salt form of BPC-157 with enhanced stability and potentially improved bioavailability compared to acetate form.
Same as BPC-157 with arginine counter-ion for improved stability in aqueous solutions.
Pentadecapeptide BPC-157 Arginate is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: 4-6 hours.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.